MARK L ENTMAN, M.D.
Osteopathic Medicine at Holcombe Blvd, Houston, TX
License number
Texas D7823
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
2002 Holcombe Blvd, Houston, TX 77030
Phone
(713) 798-4188
Personal information
See more information about MARK L ENTMAN at radaris.comName
Address
Phone
4978 Dumfries Dr, Houston, TX 77096
Houston, TX
4978 Dumfries Dr, Houston, TX 77096
4978 Dumfries, Telephone, TX 77096
Professional information
Mark Lawrence Entman, Houston TX
Specialties:
Internal Medicine, Cardiovascular Disease, Critical Care Medicine, Cardiology, Pathology
Work:
Houston Veterans Affairs Medical Center
2002 Holcombe Blvd, Houston, TX 77030
2002 Holcombe Blvd, Houston, TX 77030
Education:
Duke University(1963)
Professor At Baylor College Of Medicine
Position:
professor at Baylor College of Medicine
Location:
Houston, Texas Area
Industry:
Research
Work:
Baylor College of Medicine
-
professor
Mark Lawrence Entman, Houston TX
Specialties:
Cardiologist
Address:
2002 Holcombe Blvd, Houston, TX 77030
Education:
Duke University, School of Medicine - Doctor of Medicine
Duke University Hospital - Fellowship - Cardiology
Duke University Hospital - Fellowship - Cardiology
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine)
Selective Inhibition Of Rock1 In Cardiac Therapy
US Patent:
2006014, Jun 29, 2006
Filed:
Nov 9, 2005
Appl. No.:
11/270653
Inventors:
Lei Wei - Fishers IN, US
Robert Schwartz - Houston TX, US
Jiang Chang - Houston TX, US
Mark Entman - Houston TX, US
Robert Schwartz - Houston TX, US
Jiang Chang - Houston TX, US
Mark Entman - Houston TX, US
Assignee:
BAYLOR COLLEGE OF MEDICINE - Houston TX
International Classification:
A61K 38/17, A61K 48/00
US Classification:
514012000, 514044000
Abstract:
The present invention is directed to the treatment and/or prevention of disease as it relates to Rho kinase. In specific embodiments, disease is treated and/or prevented through the administration of an agent that selectively inhibits ROCK1. In specific embodiments, it inhibits ROCK1 and not ROCK2. In other specific embodiments, the disease is cardiac disease.
Cleaved Serum Response Factor In Cardiac Diagnosis And Therapy
US Patent:
7582478, Sep 1, 2009
Filed:
Jan 22, 2004
Appl. No.:
10/763037
Inventors:
Robert J. Schwartz - Houston TX, US
Lei Wei - Pearland TX, US
Jiang Chang - Houston TX, US
Mark Entman - Houston TX, US
Lei Wei - Pearland TX, US
Jiang Chang - Houston TX, US
Mark Entman - Houston TX, US
Assignee:
Baylor College of Medicine - Houston TX
International Classification:
C12N 5/00, C12N 5/02, A61K 48/00, A61K 38/30
US Classification:
435325, 514 12, 424 932, 424 936
Abstract:
The present invention is directed to the cleavage of serum response factor as it relates to cardiac disease. In specific embodiments, failing cardiac tissue is diagnosed in tissues comprising elevated cleavage of serum response factor. In further specific embodiments, heart failure is associated with cardiac myocyte apoptosis as a result of an increase in cleaved serum response factor, particularly by caspases.
Heart Derived Cells For Cardiac Repair
US Patent:
2004012, Jul 1, 2004
Filed:
Aug 29, 2003
Appl. No.:
10/651548
Inventors:
Michael Schneider - Houston TX, US
Hidemasa Oh - Houston TX, US
Mark Entman - Houston TX, US
Hidemasa Oh - Houston TX, US
Mark Entman - Houston TX, US
Assignee:
Baylor College of Medicine - Houston TX
International Classification:
C12N005/08
US Classification:
435/372000, 435/366000, 424/093700
Abstract:
The present invention is drawn to compositions and methods of using the same to cardiovascular disease. The compositions of the present invention are cardiac stem cells that are c-kit/CD31/CD38 and express telomerase reverse transcriptase.